Skip Navigation LinksHome > May 2009 - Volume 337 - Issue 5 > Impact of Sitagliptin on Markers of [beta]-cell Function: A...
American Journal of the Medical Sciences:
doi: 10.1097/MAJ.0b013e31818eb721
Clinical Investigation

Impact of Sitagliptin on Markers of [beta]-cell Function: A Meta-Analysis.

Riche, Daniel M. PharmD, BCPS; East, Honey E. MD; Riche, Krista D. PharmD, BCPS

Collapse Box

Abstract

Background: Progressive β-cell dysfunction and β-cell failure are fundamental pathogenic consequences of type 2 diabetes. Dipeptidyl peptidase-IV inhibitors may exhibit improvement on preclinical measures of both β-cell function, homeostasis model assessment of β-cell (HOMA-β) index, and β-cell dysfunction, proinsulin/insulin ratio (PI/IR), correlating to β-cell survival.

Research Design and Methods: A systematic literature search through July 2008 was conducted to extract a consensus of randomized, controlled trials of sitagliptin therapy on measures of β-cell function. A random-effects model meta-analysis evaluated effects on HOMA-β and PI/IR versus placebo. Several subgroup analyses, including active control, were conducted. Studies were included if they met the following criteria: (1) randomized trials on sitagliptin; (2) placebo or active control; and (3) data reported on HOMA-β or PI/IR.

Results: A total of 11 trials (n = 3039) reported effects on HOMA-β and 8 trials (n = 2325) on PI/IR versus placebo. Four trials (n = 1425) were included in the active control subgroup analysis. Sitagliptin significantly improved HOMA-β index by 12.03% [95% confidence interval (CI), 9.45-14.60] versus placebo. Sitagliptin also significantly decreased PI/IR -0.06 (95% CI, -0.08 to -0.04). Sitagliptin was inferior to active control for HOMA-β index [5.64% (95% CI, 0.38-10.90)], but not different in terms of PI/IR [0.01 (95% CI, -0.04 to 0.06)].

Conclusions: Despite significant improvement in HOMA-β index and PI/IR from placebo, there does not seem to be a benefit of dipeptidyl peptidase-IV inhibitors over other agents with respect to β-cell function/activity. Long-term prevention of β-cell dysfunction cannot be ruled out.

© Copyright 2009 Southern Society for Clinical Investigation

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.